CEO & Founder
Heeyong Lee has been working in the field of sustained release microspheres for over 20 years, starting from the time he worked as a postdoc at the University of Kentucky, where he participated in the development of a long-acting prostate cancer drug. Prior to starting G2GBIO, he worked at Peptron for 15 years as a head of R&D and Business Development. During that time, he was responsible for developing sustained-release drugs for prostate cancer, acromegaly, and type 2 diabetes and succeeded in commercializing a prostate cancer drug through technology transfer and licensing. He also contributed significantly to Peptron's listing on the KOSDAQ in 2015. Heeyong has earned his B.S. degree in biochemistry at Yonsei University and M.S. and Ph.D. degrees in life sciences at KAIST.
Senior managing director
Head of R&D
Eunyoung Seol has been in charge of developing sustained-release injections at Daewoong Pharmaceuticals, Dong Kuk Pharm, and Peptron before starting G2GBIO. He has long-standing expertise in research, clinical trials, commercialization and the processes of both spray-drying emulsification of peptides and small molecules. He graduated from Chungnam National University with a B.S. and M.S. degrees in Biochemistry.
Senior managing director
Bokman Kim has served as the director of the Manufacturing Division at Peptron, where he established a sterile microsphere production process using spray drying and oversaw construction of a clinical factory. Prior to that, he worked at LG Life Sciences for approximately 16 years. There he directed the production of various pharmaceuticals and plant construction. He holds a B.S. degree in chemical engineering from Chung-Ang University.
Business development & strategic planning
Soojung Lee has been responsible for licensing and joint development, and IP management at Peptron. Before Peptron, she had worked in drug-pricing area by using pharmacoeconomic analysis. She received her B.S. degree in microbiology and M.S. degree in genetic engineering from Seoul National University, and MBA degree from KAIST.
Development & strategic planning
Jaemook Choi has worked as a team leader in non-clinical studies, regulatory affairs and quality management for CJ CheilJedang, Daewoong Pharmaceuticals, Hanwha Chemical, and Chong Kun Dang. He has experience in the fields of the approval and commercialization of biologics and chemical pharmaceuticals. He received his B.S. and M.S. degrees from Korea University in medical laboratory science and genetic engineering respectively, and has earned a Ph.D. degree in new drug development from Chungnam National University.
Analytical research / R&D quality
HeeKyoung Choe has more than 16 years of previous research experience in at JW pharmaceutical, CKD Pharm, and Dream Pharma. After these years in the research field, she decided to change focus and moved to the pharmaceutical manufacturing site and served as the QC and QA team leader at Dream Pharma and Alvogen Korea for about 6 years. Her experience spans from pharmaceutical research and development to quality of production. HeeKyoung received her B.S. degree in chemistry education and M.S. degree in chemistry from Kyungpook National University.
CFO / Business Administration
Gyojoong Jeon worked at Medipost for 12 years in the finance department. He raised funds by building partnerships with investors through strong stockholder relationships. He communicated with major national institutions while also being responsible for managing shares, disclosure of company information, accounting, and tax. Also, he operated an internal accounting control system as the head of the department. He holds a degree in mathematics and holds a master’s degree in finance management from YeungNam University.
Research Planning & Management
She has worked in the field of pharmacokinetic research at Korea Institute of Toxicology and Kuhnil pharmaceutical company. For approximately 8 years since 2002, she has worked at the Bioequivalence bioanalysis CRO as the study director for GLP analysis of non-clinical TK and clinical PK analysis. At the SCAS-BTT Bioanalysis company, which the Biotoxtech company made a joint venture with SCAS of Japan, she has worked in the sales management and bioanalysis research field for 10 years. She has experience in increasing sales through domestic and Japan sales networking. By utilizing the sales networking, she set-up a system that can expand the range of products offered to include low molecular drugs, peptide drugs, and biosimilar bioanalysis.
She received Bachelor’s degree and Master’s degree in biochemistry from Chungbuk National University.
Raymond T. Bartus, Ph.D.
Raymond T. Bartus, the President of RTBioconsultants Inc., had worked in big pharma and emerging biotech/specialized pharmaceutical companies such as Alkermes and Ceregene. Working for over 35 years, he participated in the research and development of a wide range of novel products, of which 16 progressed into human clinical trials. Specifically, Vivitrol, Risperdal Consta, Nutropin Depot, and Bydureon are long acting microsphere SR drugs that he was involved in. Based on his wealth of experience he can be consulted during the whole process of G2GBIO’s development, and will be actively advising the company.
Jaechul Shim, Ph.D.
Jaechul Shim, CEO of SUNG & JAY LLC, worked at Pfizer and Biogen. He is an expert in overall NCE development and CDMO business. In particular, he is familiar with technology transfer, API cGMP production, process development, large scale manufacturing, and NCE R&D. He is an advisor for the GMP manufacturing process.
Sung Nyeo Shim, M.Sc.
Sung Nyeo Shim, President of SUNG & JAY LLC, previously worked at TEVA and GLAXOSMITHKLINE (GSK). She is an expert in R&D, cGMP, quality assurance and compliance, In addition, she has experience with technology transfer, and she is an advisor for product development and documentation guidelines.
Hwan-gu Kang, Ph.D.
Hwan-gu Kang is a professor of pharmacology and toxicology at Semyung University’s Department of Animal Bio-Health. He also serves as the academic chair of the Korea Society of Preventive Veterinary Medicine and the Vice President of the Toxicology Society. He worked in national agencies, such as the Animal and Plant Quarantine Agency, the Ministry of Food and Drug Safety, and the Rural Development Administration. With this strong and diverse career, he offers valuable advice on nonclinical toxicology and regulatory affairs for veterinary medicine.
Dr. Mark Tracy
Dr. Mark Tracy is Founder and President, Tracy BioConsulting, LLC (TBC). Previously, he worked in senior roles at two biotechnology companies, Alnylam and Alkermes. Dr. Tracy is known internationally for developing innovative first-in class complex injectable and nucleic acid therapeutics. Dr. Tracy played a key role in developing Onpattro®, the first RNAi therapeutic approved by the FDA, EMA and other regulatory agencies worldwide. He also developed several complex injectable microsphere sustained release products that have been commercialized including Vivitrol®, Bydureon®, and Nutropin® Depot, which was the first long acting protein product approved by the FDA. He has extensive experience in the development of nano and microparticle-based products and other sterile injectable formulations from research through IND filing and commercialization. Dr. Tracy is a Past-President and Fellow of the Controlled Release Society (CRS) and a Fellow of the American Institute for Medical Biological Engineering (AIMBE).